## Drug of Choice for Shigella Infection **Key Point:** Fluoroquinolones (especially ciprofloxacin) are the current first-line agents for Shigella dysentery in both children and adults, particularly in endemic areas with high resistance rates. ### Current Treatment Guidelines **High-Yield:** The choice of antibiotic for Shigella has evolved significantly due to widespread resistance patterns in India: | Antibiotic | Status | Reason | |---|---|---| | Ciprofloxacin | **First-line (current)** | Excellent intracellular penetration, oral bioavailability, effective against most strains including resistant S. sonnei | | Ampicillin | Obsolete | High resistance rates (>70%) in India; no longer recommended | | TMP-SMX | Obsolete | Widespread resistance; historically used but now ineffective | | Ceftriaxone | Alternative | Reserved for severe invasive disease or fluoroquinolone resistance; not first-line for uncomplicated dysentery | ### Mechanism of Fluoroquinolone Action **Clinical Pearl:** Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, achieving excellent concentrations in intestinal mucosa and intracellular sites where Shigella resides. This is crucial because Shigella is an intracellular pathogen that invades epithelial cells. ### Dosing in Children - **Ciprofloxacin:** 10–15 mg/kg/day in 2 divided doses for 3–5 days (oral) - Duration: Typically 3–5 days for uncomplicated dysentery - Severe or invasive disease: Consider IV ceftriaxone or azithromycin **Warning:** Although fluoroquinolones are traditionally avoided in pediatric patients due to concerns about cartilage toxicity, they are now recommended by WHO and Indian guidelines for Shigella in children when resistance to other agents is high. ### Resistance Patterns in India **Mnemonic: FAST** — Fluoroquinolone-resistant, Ampicillin-resistant, Sulfonamide-resistant, TMP-SMX-resistant strains are now common in endemic regions. **High-Yield:** Multi-drug resistant (MDR) Shigella strains are prevalent in India, making older agents like ampicillin and TMP-SMX unreliable. Ciprofloxacin remains effective with resistance rates typically <15% in most Indian centers. ### Alternative Agents - **Azithromycin:** Emerging option for fluoroquinolone-resistant strains; 10 mg/kg/day for 3 days - **Ceftriaxone:** Used in severe invasive disease, bacteremia, or when fluoroquinolones are contraindicated - **Pivmecillinam:** Effective but less commonly available in India [cite:Park 26e Ch 3]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.